瑞康醫藥(002589.SZ)擬斥7000萬元參設杭州啟真投資
格隆匯2月21日丨瑞康醫藥(002589.SZ)公佈,公司於2020年2月21日召開第四屆董事會第四次會議審議通過了《關於參與杭州啟真未來創新股權投資合夥企業(有限合夥)暨對外投資的議案》,同意公司參與專業投資機構浙商創投股份有限公司(“浙商創投”)旗下的杭州啟真未來創新股權投資合夥企業(有限合夥)(“杭州啟真投資”)。杭州啟真出資總規模為人民幣5億元,其中瑞康醫藥出資7000萬元。
杭州啟真未來創新股權投資合夥企業(有限合夥)從事創業投資、股權投資業務,創造滿意的投資回報的合作目的。主要投資於浙江大學醫學中心及浙大校友的創新臨牀技術、生物醫藥、醫療器械等領域內具有創新優勢和發展前景、能實現科研成果產業化的醫療健康項目和投資於單一項目的子基金,重點投資對浙江省經濟社會發展具有明顯帶動作用的重大創新項目和創新型企業,科創板重點培育企業,以及種子期、初創期、成長期等創業早期的科技型中小微企業和高新技術企業,並根據浙江省委、省政府戰略部署及時作出調整。
此次投資有限合夥企業,參與醫療產業基金投資相關業務,有利於公司在未來業務重點佈局地區的業務拓展,與地方政府財政引導基金通力合作,對產業鏈進行前瞻性佈局,增強公司的核心競爭力和持續盈利能力。公司此次對外投資設立有限合夥企業是基於整體的發展戰略基礎上進行的,符合公司的戰略佈局及發展需求,能夠充分發揮公司與未來重點佈局地區政府財政引導基金以及專業投資機構的互補優勢,增強可持續發展能力。此次投資資金來源為公司自有資金,不會對公司財務及經營狀況產生不利影響,不存在損害公司及全體股東利益的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.